Novo Nordisk's new long-acting insulin, Tresiba, has been shown to be effective and safe for long-term use in children and young adults with type 1 diabetes, according to new data from a late-stage trial presented on Tuesday.
Novo Nordisk's new long-acting insulin, Tresiba (insulin degludec), has been shown to be effective and safe for long-term use in children and young adults with type 1 diabetes, according to new data from a late-stage trial presented on Tuesday.
Long-acting Tresiba is an important product for future growth at the company, which is the world's top insulin maker.
However, US regulators have refused to approve Tresiba due to potential heart risks, dealing a blow to the company. Tresiba was approved in the European Union last year.
Results of the first trial to look at the long-term safety of Tresiba in children aged 1 to 18 years over a 52-week period showed it improved blood sugar control without increasing the risk of hypoglycaemia.
Read the complete report: http://bit.ly/1uUeUWl
Source: Medscape
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Balancing Care Access and Fragmentation for Better Outcomes in Veterans With Diabetes
April 22nd 2021The authors of a study in the April 2021 issue of The American Journal of Managed Care® discuss the possible reasons behind the link between care fragmentation and hospitalizations in veterans with diabetes, as well as potential opportunities to address disjointed care in the context of the widespread telehealth uptake seen during the COVID-19 pandemic.
Listen
What We’re Reading: ACA Perception; FDA Blood Sugar Warning; AI and Physician Burnout
February 22nd 2024More than half of US adults have a favorable view of the Affordable Care Act (ACA); smartwatches and rings that claim to measure blood sugar levels without piercing the skin could be dangerous and should be avoided; many believe artificial intelligence (AI) could be the solution to physician burnout.
Read More
Advancements in Diabetes Technology: Coverage, Challenges, and Pregnancy Considerations
February 15th 2024Expert interviews highlight advancements and challenges in diabetes care technology, including automated insulin delivery systems and continuous glucose monitors, as well as improvements in insurance coverage.
Read More